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Abstract
Background: Antiretrovirals used to treat HIV-infected patients have the potential to adversely
affect serum lipid profiles and increase the risk of cardiovascular disease which is an emerging
concern among HIV-infected patients. Since boosted atazanavir and efavirenz are both considered
preferred antiretrovirals a head to head comparison of their effects on serum lipids is needed.
Aim: The primary objective of the study was to compare the effects of atazanavir (boosted and
unboosted) and efavirenz based regimens on serum lipid profiles.
Study Design: Prospective cohort study nested within three ongoing cohorts of HIV-infected
individuals.
Study Population and Methods: Participants initiating either atazanavir or efavirenz based
regimens with documented pre- and post-initiation lipid values. Multivariate linear regression was
conducted to estimate adjusted mean differences between treatment groups for high density
lipoprotein cholesterol (HDL-c), non-HDL-c, and log total cholesterol (TC) to HDL-c ratio
outcomes; log-linear regression models were used to estimate differences in prevalence of low
HDL-c and desirable TC.
Results: The final study population was comprised of 380 efavirenz and 281 atazanavir initiators.
Both atazanavir and efavirenz users had increases in serum HDL-c and decreases in TC/HDL ratio.
In comparison to individuals initiating efavirenz, boosted atazanavir users on average had lower
HDL-c (-4.12 mg/dl, p < 0.001) and non HDL-c (-5.75 mg/dl, p < 0.01), but similar declines in TC/
HDL ratio.
Conclusion: Both efavirenz and atazanavir-based regimens (boosted and unboosted) resulted in
similar beneficial declines in the TC/HDL ratio.
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Background
Use of antiretrovirals can adversely affect serum lipid lev-
els and contribute to cardiovascular risk, an emerging con-
cern among HIV-infected patients. [1,2] Therefore, careful
comparisons of the effects of commonly used antiretrovi-
rals on serum lipids are needed. Efavirenz (EFV) and ata-
zanavir (TAZ) are two commonly used antiretrovirals. The
results of a phase 3 study comparing EFV and TAZ based
regimens demonstrate similar virologic efficacy with the
use of either agent, though EFV use resulted in dyslipi-
demia while TAZ use did not. [3] However, the current
treatment paradigm favors the use of TAZ in combination
with low dose ritonavir (boosted TAZ) and not unboosted
TAZ.[4] Since, the addition of ritonavir to TAZ results in
dyslipidemia [5], there is a need to compare and contrast
the magnitude of the effects of boosted TAZ and EFV
based regimens on serum lipids. To this end, we utilized
data from a racially diverse group of HIV-infected individ-
uals with the specific aims of comparing the effects of
boosted TAZ and EFV on serum lipids. In this study we
observed beneficial changes, namely declines in total cho-
lesterol (TC)/high density lipoprotein cholesterol (HDL)
ratio and increases in HDL-c, in serum lipids with all three
regimens (unboosted TAZ, boosted TAZ, and EFV)
Methods
Study population
Data were collected from participants enrolled in three
independent ongoing prospective cohort studies: the Mul-
ticenter AIDS Cohort Study (MACS), the Women's Intera-
gency HIV Study (WIHS), and United States Navy
beneficiaries followed at two of three Navy HIV Evalua-
tion and Treatment Units. Recruitment and follow-up
procedures for all three patient groups have been previ-
ously described. [6-8] Eligible subjects initiated regimens
of two or more nucleoside reverse transcriptase inhibitors
(NRTI) with either 1) EFV or 2) TAZ or boosted TAZ, using
these criteria 1,020 EFV and 655 TAZ initiators were iden-
tified. Excluding initiators who did not have lipids meas-
ured both pre and post initiation (430 EFV and 108 TAZ),
those missing information on antiretroviral use during
the study period (41 EFV and 50 TAZ), those using both
agents at the pre visit (137 EFV and 179 TAZ), or using
lipid lowering therapy at the pre or first post visit (32 EFV
and 37 TAZ), 380 EFV and 281 TAZ initiators comprised
our final study population. Complete antiretroviral his-
tory including start and stop dates were determined from
chart review, electronic pharmacy records, or self-report
assessed using questionnaires and photo cards. Individu-
als were followed up to the first occurrence of 1) discon-
tinuation of EFV or TAZ (29% EFV, 30% TAZ), 2)
initiation of lipid-lowering therapy (4% EFV, 1% TAZ), or
3) last lipid measurement within two years of initiating
EFV/TAZ (67% EFV, 68% TAZ). There was no difference in
censoring between the two ARV groups (p = 0.21). EFV or
TAZ was used <1 to 6 months prior to the first post visit
for 76% of participants, 6–12 months for 19%, and 12–
24 months for 5%.
Outcome ascertainment
MACS began routine measurement of serum lipids for all
participants in April 1999; WIHS began in April 2004.
Baseline levels were measured retrospectively for selected
MACS participants, and for all WIHS participants seen
between October 2001 and March 2004. Navy partici-
pants had lipids measured at all visits. Both MACS and
WIHS used a central laboratory, while the Navy partici-
pants used their hospital laboratories for lipid measures.
Three continuous and two binary outcomes based on the
updated National Cholesterol Education Program
(NCEP) ATP III Guidelines [9] were defined: 1) high-den-
sity lipoprotein cholesterol (HDL-c measured in mg/dL),
2) non-HDL-c (mg/dL) calculated as total cholesterol
(TC) minus HDL-c, 3) natural log-transformed TC to
HDL-c ratio, 4) low HDL-c (<40 vs. ³ 40 mg/dL), and 5)
desirable TC (<200 vs. ³ 200 mg/dL).
Statistical methods
Multivariate linear regression was used to estimate
adjusted mean differences between treatment groups for
HDL-c, non-HDL-c, and log TC to HDL-c ratio; multivari-
ate log-linear regression was used to estimate prevalence
ratios for low HDL-c and desirable TC. For each outcome,
two models with different potential confounders were
included. Model 1 adjusted for sex, race/ethnicity, age at
EFV/TAZ initiation, history of diabetes mellitus or thyroid
dysfunction, baseline hepatitis C virus antibody status,
pre-initiation HDL-c and non-HDL-c, CD4+ cell count,
HIV-1 viral load, pre-initiation ART- and class- (NNRTI/
PI) naïve status, years of HAART exposure and follow up
time. In model 2, we further adjusted for post-initiation
CD4+ count and HIV-1 viral load and type of NRTI back-
bone. Two potential a priori effect modifiers of regimen
with dyslipidemia outcomes were also investigated: (a)
follow-up time (time elapsed between the date of EFV/
TAZ initiation and the date lipids were collected) and (b)
race/ethnicity. We specifically evaluated the role of race
and ethnicity, given recent reports that suggest the effects
of antiretrovirals on serum lipids are modified by host
characteristics including race. [10]
For each model, generalized estimating equation methods
(GEE) were used to account for within-person correlation
of repeated measurements. Data were complete for all
cofactors for 357 (94%) of EFV and 259 (94%) of TAZ
users; (single-chain) Markov-chain Monte Carlo multiple-AIDS Research and Therapy 2009, 6:13 http://www.aidsrestherapy.com/content/6/1/13
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imputation methods were used to complete missing cov-
ariate data. [11]
Results
The study population consisted of 380 EFV initiators and
281 TAZ initiators (79% of whose regimens were
boosted), racial minorities (47% African-Americans and
16% Hispanics) and women (48%) were well repre-
sented. Table 1 provides the baseline characteristics of the
two groups. Adjusted for baseline CD4 counts, follow-up
time, regimen type, and sex, CD4+ cell counts increased
on average by 57 cells per year. The proportion of individ-
uals having an undetectable viral load (i.e. < 80 copies/
ml) increased from 18% to 63% among all subjects. At
any point in time, on average, TAZ users had lower CD4+
cell count (-26, p = 0.05) and lower odds of an undetect-
able viral load (0.60, p < 0.0001).
The first two columns of Table 2 show the mean or preva-
lence of each of the outcomes at the baseline (pre-initia-
tion) and post-initiation visits. The subsequent columns
of Table 2 show the differences in post-initiation markers
relative to those initiating EFV. There were no differences
in the baseline TC, non HDL-c, or HDL-c among EFV and
TAZ users. After adjusting for potential confounders, both
boosted and unboosted TAZ initiators showed a smaller
increase in HDL-c than EFV initiators. Those initiating
boosted (but not unboosted) TAZ also showed lower non-
HDL-c as compared to EFV initiators. All three regimens
resulted in similar declines in TC/HDL ratios. The propor-
tion of subjects who met study specified criteria for low
HDL-c declined with all three regimens and was not statis-
tically different among the three groups. Subjects meeting
study specified criteria for desirable cholesterol were sim-
ilar across treatment groups. The interaction between reg-
imen type and follow-up time was not significant in any
model.
Changes in serum lipids varied by race; in comparison to
Caucasians, mean post-initiation HDL-c was significantly
higher (+5 mg/dL, p < 0.0001) among African-Americans,
while Hispanics had significantly lower mean non-HDL-c
(-5 mg/dl, p = 0.04). In African-Americans, the TC/HDL
ratio and proportion who met study specified criteria for
low HDL-c were significantly lower by 8% (p < 0.0001)
and 34% (p = 0.0001) respectively. The TC/HDL was also
significantly lower in Hispanics by 5% (p = 0.03). How-
ever, the interaction between regimen type and race was
not significant in any model.
In a separate analysis to assess possible bias resulting from
excluding individuals who had post-initiation lipids but
were missing pre-initiation measures, we ran additional
multivariate linear regression models using GEE methods
for HDL-c and non-HDL-c, adjusting for sex, race, age, and
follow-up time, first excluding those who were missing
pre-initiation measures (MPM) and then including them.
When the MPM individuals were excluded, TAZ users had
5.97 mg/dL lower HDL-c than EFV users (p < 0.001);
when they were included, TAZ users had 6.48 mg/dL
lower HDL-c (p < 0.001). For non-HDL-c, the differences
were -7.46 mg/dL (p = 0.046) excluding MPM individuals
and -13.86 mg/dL (p < 0.001) including them
Discussion
The results of our study are similar to those observed in a
randomized clinical trial comparing EFV and unboosted
TAZ in naïve patients.[3] In this study, those initiating EFV
had greater increases in TC and HDL-c. Our results would
suggest that the addition of low dose ritonavir to TAZ
appears not to negate these effects. Interestingly, the use of
all three regimens (EFV, boosted and unboosted TAZ)
were associated with beneficial changes in serum lipids in
comparison to baseline namely increases in HDL-c, and
decreases in TC/HDL ratio. In addition, the proportion of
patients who switched HDL-categories (low to normal)
increased with all three regimens. However, in compari-
son to boosted TAZ-users, EFV-users had greater increases
in both HDL and non-HDL-c. Whether differences in the
class of lipids preferentially affected by these agents will
influence the risk of future coronary artery disease is
unknown and warrants study.
Given the racial diversity of the study population we were
also able to evaluate the effects of these agents by race.
African-Americans and Hispanics demonstrated a less
atherogenic lipid profile in response to therapy with
either agent. It's unlikely that lifestyle factors alone
account for the differences we observed; genetic variations
probably played a role. Differences in host genetic charac-
teristics are known to influence levels of both EFV and
TAZ and serum lipid levels independently. [12,13]
Increases in HDL-c and non HDL-c in response to ART are
associated with polymorphisms in the cholesterol ester
transfer protein and multi-drug resistance genes. [14]
Thus far, pharmacogenetic studies have been conducted
in racially homogeneous populations; futures studies
should include racially representative population, to help
explain these differences. [14,15]
One possible criticism regarding our study is its observa-
tional design with the potential for selection bias and con-
founding by unmeasured variables. As described
previously, we conducted a sub-group analysis in patients
with missing pre-initiation lipid measures. Similar results
were observed among those with and without pre-initia-
tion measures, thereby indicating that a selection bias was
probably not operational and further validating our
results.AIDS Research and Therapy 2009, 6:13 http://www.aidsrestherapy.com/content/6/1/13
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Table 1: Baseline characteristics of 380 efavirenz and 281 atazanavir initiators.









Male 63% 38% <0.0001
Race/Ethnicity <0.0001
Caucasian (Hispanic & Non Hispanic) 43% 28%
African-American (Hispanic & Non-Hispanic) 46% 49%
Hispanic (non-white, non-black) & other 11% 22%
Age at switch/initiation 41 (34, 47) 41 (35, 46) 0.91
Medical History
Diabetes Mellitus 11% 17% 0.03
Thyroid Disease 3% 6% 0.07
Hepatitis C antibody status 15% 19% 0.18
Treatment Characteristics





ART-naïve at initiation 34% 12% <0.0001
Class-naïve at initiation 80% 30% <0.0001
Years of HAART exposure at initiation 0.5 (0.1, 2.9) 3.6 (1.2, 5.7) <0.0001
Atazanavir regimen included Ritonavir 79%AIDS Research and Therapy 2009, 6:13 http://www.aidsrestherapy.com/content/6/1/13
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ARV Group Pre Post Unadjusted Post 
Difference
Model 1* Adjusted 
Difference
p-value Model 2** Adjusted 
Difference
p-value
HDL-c (mg/dL) EFV 39 46 Ref Ref Ref
Unboosted TAZ 39 42 -4 -3.92 0.003 -3.43 0.008
Boosted TAZ 38 41 -5 -4.12 <0.001 -4.00 <0.001
Non- HDL-c 
(mg/dL)
EFV 131 136 Ref Ref Ref
Unboosted TAZ 117 131 -5 -1.92 0.55 -1.08 0.73
Boosted TAZ 126 125 -11 -5.75 0.01 -4.57 0.04
TC/HDL EFV 4.45 4.02 Ref Ref Ref
Unboosted TAZ 4.45 4.10 1.99 4.41 0.14 3.94 0.19
Boosted TAZ 4.10 3.97 -1.24 2.62 0.21 3.40 0.11
Prevalence
Binary Lipid Outcome ARV Group Pre Post Unadjusted Post 
Prevalence Ratio
Model 1* Adjusted 
Prevalence Ratio
p-value Model 2** Adjusted 
Difference
p-value
HDL<40 (mg/dL) EFV 52% 33% Ref Ref Ref
Unboosted TAZ 55% 39% 1.18 1.05 0.79 1.01 0.95
Boosted TAZ 53% 42% 1.27 1.18 0.18 1.19 0.17
TC<200 (mg/dL) EFV 74% 62% Ref Ref
Unboosted TAZ 85% 73% 1.18 1.07 0.59 1.05 0.71
Boosted TAZ 81% 78% 1.26 1.16 0.09 1.13 0.16
* Adjusted for sex, race, age, history of chronic diseases, pre-initiation HDL and non-HDL cholesterol, CD4, HIV RNA, therapy, and follow-up time
** In addition to variables above, also adjusted for post-initiation CD4, HIV RNA, and type of NRTI backbone
HIV biomarkers prior to initiation
CD4+ cell count 332 (216, 464) 289 (202, 462) 0.11
Log10 HIV RNA 4.15 (2.65, 4.75) 4.01 (2.59,4.76) 0.42
Viral load <80 copies/mL 19% 17% 0.50
Post-initiation HIV characteristics***
CD4+ cell count 434 (303, 581) 410 (241, 575) 0.02
Log10 HIV RNA 1.90 (1.90, 2.38) 1.90 (1.90, 2.51) <0.0001
Viral load <80 copies/mL 68% 58% 0.0003
NRTI backbone included
TDF or ABC & D4T, DDI, or AZT 19% 28% 0.0003
TDF or ABC but not D4T, DDI, or AZT 32% 58% <0.0001
D4T, DDI, or AZT but not TDF or ABC 49% 14% <0.0001
* Median (IQR) for continuous characteristics ** From chi-square tests (categorical) or Wilcoxon rank sum test (continuous) *** Collapsed across all follow-up
Table 1: Baseline characteristics of 380 efavirenz and 281 atazanavir initiators. (Continued)AIDS Research and Therapy 2009, 6:13 http://www.aidsrestherapy.com/content/6/1/13
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Conclusion
In conclusion, clinicians treating HIV-infected patients
can be reassured that the use of both boosted TAZ and
EFV-based regimens results in a favorable lipid profile, as
measured by changes in serum TC/HDL ratio. However,
since subtle metabolic effects are likely to become increas-
ingly important in decisions regarding optimal drug ther-
apy in HIV-infected patients, future studies should explore
the effects of drugs on lipoprotein subclasses and the
effects of host genetics on metabolic profiles. [16]
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